Previous 10 | Next 10 |
Former Worldwide Head of Licensing and Acquisition and Knowledge Management at Merck & Co., where he led the completion of more than150 business development transactions Former Global Head of Infectious Diseases for Johnson & Johnson Pharmaceuticals Former Ve...
Nes-Ziona, Israel, May 19, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis and solid tumors, today announced that compan...
In a little over a year, the market has gone from sell "old economy", companies that make something and earn money, to sell companies that don’t make things and earn money. We are now at the stage where nobody cares. don’t buy anything, whether it makes makes "things" or...
Nes-Ziona, Israel, May 10, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that company management will be presenting scientific and clinical overviews in thr...
Mesothelioma is one of the deadliest solid cancers, with few treatment options, all of which have limited efficacy. Immune checkpoint inhibitors targeting CTLA4 and PD1 are FDA-approved as a first-line treatments for patients with unresectable malignant pleural mesothelioma Up t...
Enlivex Therapeutics (NASDAQ:ENLV) said it was issued two U.S. patents related to claims covering methods of treating sepsis with Allocetra. The company noted that U.S. Patent No. 11,304,976 and 11,318,163, each provide intellectual property (IP) protection in the U.S. un...
Nes-Ziona, Israel, May 05, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the issuance of U.S. Patent Nos. 11,304,976 and 11,318,163. Each patent provides En...
Nes-Ziona, Israel, May 02, 2022 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced the acceptance of an abstract for a poster presentation at the upcoming 2022 Americ...
Envilex Therapeutics press release (NASDAQ:ENLV): FY Net loss of $14.4M As of December 31, 2021, Enlivex had cash, cash equivalents, short term deposits , and marketable securities of $84.1 million. For further details see: Envilex Therapeutics reports FY results
Development of frozen formulation Allocetra™, a primary cornerstone of Enlivex’s R&D efforts during the last two years, was successfully completed in Q1 2022, twelve months ahead of schedule Frozen formulation Allocetra™ is expected to vastly improve...
News, Short Squeeze, Breakout and More Instantly...
Enlivex Therapeutics Ltd. Company Name:
ENLV Stock Symbol:
NYSE Market:
Enlivex Therapeutics Ltd. Website:
• First study of Allocetra TM in psoriatic arthritis, a chronic inflammatory condition that causes joint pain, swelling and stiffness, affects as many as 30% of people with psoriasis 1 , and has limited treatment options Nes-Ziona, Israel, July 23, 2024 (GLOB...
ORLANDO, FL / ACCESSWIRE / July 19, 2024 / RedChip Companies will air interviews with Enlivex Therapeutics Ltd. (Nasdaq:ENLV) and Biotricity, Inc. (Nasdaq:BTCY) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV, this Saturday, July 20, at 7 p.m. Eastern T...
First patient dosed with Allocetra TM in thumb osteoarthritis, a degenerative, debilitating and progressive disease that affects millions of people Thumb osteoarthritis currently has no FDA-approved therapy and no effective long-term treatments Ness-Ziona, Israel, June 24, 2024 (GLO...